Antibodies

29 May 2018 Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin®
29 May 2018 Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA®,” Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy
29 May 2018 Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
28 May 2018 UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
27 May 2018 Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
25 May 2018 Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer
25 May 2018 Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
25 May 2018 Lupin submits Marketing Authorization Application for Etanercept Biosimilar in Europe
24 May 2018 Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin's Lymphoma
24 May 2018 Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
23 May 2018 F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
23 May 2018 Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
23 May 2018 Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform
23 May 2018 Apogenix Provides Update on Clinical Development of Asunercept
23 May 2018 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial
23 May 2018 Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration
23 May 2018 Efficacy and safety of Cytotect® CP was demonstrated in patients after stem cell transplantation
22 May 2018 CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
22 May 2018 FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
22 May 2018 Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
22 May 2018 GamaMabs Pharma to present at 2018 ASCO Annual Meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers
18 May 2018 Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
17 May 2018 Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus
17 May 2018 Innovent Biologics Announces the Study Result of its Anti-PD-1 Antibody in Hodgkin Lymphoma
17 May 2018 Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top